Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
about
Measuring response in the gastrointestinal tract in systemic sclerosisPredictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohortDevelopment of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseasesExperience with rituximab in scleroderma: results from a 1-year, proof-of-principle studyComplementary and alternative medicine use was associated with higher perceived physical and mental functioning in early systemic sclerosis.Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicineValuation of scleroderma and psoriatic arthritis health states by the general public.Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.Quality of life among testicular cancer survivors: a case-control study in the United StatesDeterminants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort.The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis.Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyAssessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosisReliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisEvaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life StudyA systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples.Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.The symptom burden index: development and initial findings from use with patients with systemic sclerosis.Development of a provisional core set of response measures for clinical trials of systemic sclerosis.Responsiveness and minimally important difference for the patient-reported outcomes measurement information system (PROMIS) 20-item physical functioning short form in a prospective observational study of rheumatoid arthritis.No evidence for a role of the proximal IL-6 G/C -174 single nucleotide polymorphism in Italian patients with systemic sclerosis.Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis.The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis.Assessment of skin involvement in systemic sclerosis.
P2860
Q27022416-1A58D67D-9EF5-4AD4-BE60-5C0B6438A14BQ28743863-43E26526-BA18-426C-B9E3-CA1F43972064Q30413598-5F3E447C-D403-4313-9543-8F5EB4AE40A9Q33515869-2F11D337-99C2-4943-A946-72F5BA8A161AQ33588875-3CBD4A47-64C3-46E0-AA64-8405C1E1A998Q33874256-A57F5BF9-E18C-4812-BF52-E6D929721AA7Q33945954-F0C0D155-0AF4-4661-A713-352928E8F253Q34221999-E086D082-EBEE-4C79-8AF7-EA8FDE909A13Q35048672-29E84E15-E251-4862-AD4A-405F2E4901EAQ35146293-571D6972-6925-4A9C-B67D-C2668089055DQ35156880-A2FC9AA2-F5F4-4F71-970F-8A665CA9A7FFQ35214646-1D929DD7-2CA1-4433-BA28-1BFA41F34817Q35638054-8B25C85E-3580-4F83-88A9-EFF82F28F113Q35649141-769178E0-FC7E-41E6-885B-6E5D82697A85Q35781172-0B7CB097-5934-43DD-84CA-41429A87BEDDQ35851777-F0233B57-FEA7-44FF-B103-E24BBFB4D759Q35878701-5CD08937-DF29-4DD5-9AF6-1C3D46CADC6CQ35977294-DE48C292-AD2A-4A6A-9643-A69403266757Q36733749-07E9701A-DAA3-4DB0-A859-F0ED3BA04DC4Q36893043-118D4952-EFE6-4440-A865-B750C0DE734DQ36930712-6BAC8B47-13F1-4BA3-9FEE-B0710DDA9963Q37013037-E85A9F9E-92A6-47ED-AB8B-048A6D5E49EBQ37301159-236E0F75-F30E-49C3-A0E0-286121FC76F1Q37460765-49245031-80FC-4CBE-80A5-8330A8B36366Q37460792-3BF05832-7ACE-492B-BB08-1F64C58D58FFQ37685913-B84FED28-DB1B-494E-BD81-1C0BB69B254DQ42914065-BDA1B2DA-B069-4A77-8134-64A2F23CF31BQ46255484-AC7A07F2-77AF-4069-84D2-AF4165B54DBEQ47549780-008AD7BA-3223-4F9F-9840-494796A11B3DQ47583542-4311695C-1DB0-49C8-B284-F601F0F16361Q47835767-76A1C919-658E-4219-9CD6-0475731C91B6
P2860
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Responsiveness of the SF-36 an ...... emic sclerosis clinical trial.
@en
type
label
Responsiveness of the SF-36 an ...... emic sclerosis clinical trial.
@en
prefLabel
Responsiveness of the SF-36 an ...... emic sclerosis clinical trial.
@en
P2093
P1476
Responsiveness of the SF-36 an ...... temic sclerosis clinical trial
@en
P2093
Daniel E Furst
David H Collier
Dinesh Khanna
Fredrick M Wigley
Grace S Park
James R Seibold
Jeonglim Yoon
Joseph H Korn
Larry W Moreland
Maureen D Mayes
P304
P407
P577
2005-05-01T00:00:00Z